|
| Clinical efficacy of Xuebijing combined with ulinastatin in treatment of burn sepsis: a systematic review |
| Hits 1591 Download times 1154 Received:December 21, 2018 |
| View Full Text View/Add Comment Download reader |
| DOI
10.11656/j.issn.1672-1519.2019.03.13 |
| Key Words
Xuebijing;Ulinastatin;burn;sepsis;systematic review |
| Author Name | Affiliation | | PENG Deming | The Affiliated Hospital of Nankai University, Tianjin Fourth Hospital, Tianjin 300222, China |
|
| Abstract
|
| [Objective] To systematically evaluate and discuss the clinical efficacy of Xuebijing combined with ulinastatin in the treatment of burn sepsis.[Methods] Chinese knowledge network,VIP database,Wanfang digital periodical,Chinese biomedical literature database,PubMed and Cochrane library full text database were retrieved. The retrieval years were all from the building to April 2018 and were searched and included in the randomized pairs of the clinical efficacy of Xuebijing combined with ulinastatin in the treatment of patients with burn sepsis.,Evaluated the quality of the included literatures according to the Cochrane risk bias assessment tool. RevMan 5.3 analysis was used for Meta-analysis. Results a total of 9 randomized controlled clinical trials were included,of which 308 patients in the treatment group were treated with Xuebijing combined with ulinastatin on the basis of conventional treatment such as burn shock,fluid resuscitation,anti-infection and nutritional support,and 301 patients in the control group were given the same routine treatment regimen as the treatment group.[Results] Compared with the control group,there was no significant difference in the level of calcitonin (PCT) in the treatment group (SMD=-1.70,95% CI=-3.65~-0.26,P=0. 09),and the level of C reactive protein (CRP) in the treatment group was significantly lower (SMD=-2.94,95% CI=-4.54~-1.33),and the level of interleukin decreased significantly. Low (SMD=-3.52, 95% CI=-4.72~-2.33,P<0.000 01);the level of lipopolysaccharide (LPS) decreased (SMD=-1.00,95% CI=-1.68~-0.316,P=0.004),and the level of tumor necrosis factor (TNF-α) decreased significantly (SMD=-1.71,95% CI=0.04);prothrombin time (PT) prolonged significantly (SMD=1.54,95% CI=0.52~2.56,P=0.003);activated partial prothrombin kinase time (APTT) prolonged (MD=4.88,95% CI=3.29~6.46,P<0.000 01);fibrinogen (FIB) level decreased significantly (MD=-1.50,95% CI(-1.72~-1.28),P<0.000 01);D-Dimer (DD) level significantly decreased significantly (MD=-146.16,95% CI=-171.40~-120.92,P<0.000 01);the above differences were statistically significant (P<0.05).[Conclusion] Xuebijing combined with ulinastatin can improve the levels of inflammatory factors such as CRP,IL-6,IL-10,LPS and TNF-alpha in patients with burn sepsis,and can obviously improve the blood coagulation indexes such as PT,APTT,FIB and D-D,alleviate the systemic inflammatory reaction of sepsis after burn and improve the hypercoagulable state of the blood,which is worthy of a significant effect. Clinical popularization and application. |
|
|
|
|
|
|
|
